Table 1 FDA approved cancer immunotherapies (including immune checkpoint therapies and adoptive cell therapies)
Category | Target | Name | Indication | Source |
|---|---|---|---|---|
Immune Checkpoint Therapeutic (ICI) | PD-1 or PD-L1 | Nivolumab (Opdivo) | Various cancers (e.g., Melanoma, Non-Small Cell Lung Cancer, etc.) | (1) |
Pembrolizumab (Keytruda) | Various cancers (e.g., Melanoma, classical Hodgkin Lymphoma, Primary Mediastinal B-cell Lymphoma, etc.) | (2) | ||
Atezolizumab (Tecentriq) | Non-Small Cell Lung Cancer, Urothelial Carcinoma, and Breast Cancer | (3) | ||
Cemiplimab (Libtayo) | Cutaneous Squamous Cell Carcinoma | (4) | ||
Durvalumab (Imfinzi) | Non-Small Cell Lung Cancer | (5) | ||
Avelumab (Bavencio) | Merkel Cell Carcinoma, and Urothelial Carcinoma | (6) | ||
CTLA4 | Ipilimumab (Yervoy) | Melanoma, Renal Cancer, and MSI | (7) | |
Chimeric Antigen Receptor T-cell Therapy (CAR-T) | CD19 | Axicabtagene ciloleucel (Yescarta) | Non-Hodgkin Lymphoma | (8) |
Tisagenlecleucel (Kymriah) | Non-Hodgkin Lymphoma | (9) |